GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
J Pathol Transl Med. 2017;51(2):152-158.   Published online 2017 Feb 21     DOI: https://doi.org/10.4132/jptm.2016.11.03
Citations to this article as recorded by Crossref logo
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
Norimitsu Kasahara, Kyoichi Kaira, Pinjie Bao, Tetsuya Higuchi, Yukiko Arisaka, Bilguun Erkhem-Ochir, Noriaki Sunaga, Yoichi Ohtaki, Toshiki Yajima, Takayuki Kosaka, Tetsunari Oyama, Takehiko Yokobori, Takayuki Asao, Masahiko Nishiyama, Yoshito Tsushima,
Lung Cancer.2018; 119: 71.     CrossRef
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo, Juan Wang, Jietian Jin, Hao Chen, Zijun Zhen, Wenqi Jiang, Tongyu Lin, Huiqiang Huang, Zhongjun Xia, Xiaofei Sun
Translational Oncology.2018; 11(3): 779.     CrossRef
Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
Margarita Kirienko, Martina Sollini, Arturo Chiti
Clinical and Translational Imaging.2018; 6(6): 417.     CrossRef
New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017
J. Han van Krieken
Journal of Hematopathology.2017; 10(1): 25.     CrossRef
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
David J. Pinato, James R. Black, Sebastian Trousil, Roberto E. Dina, Pritesh Trivedi, Francesco A. Mauri, Rohini Sharma
OncoImmunology.2017; 6(11): e1358332.     CrossRef